Verition Fund Management LLC Janux Therapeutics, Inc. Transaction History
Verition Fund Management LLC
- $23.6 Billion
- Q4 2024
A detailed history of Verition Fund Management LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 5,618 shares of JANX stock, worth $202,304. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,618Holding current value
$202,304% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding JANX
# of Institutions
228Shares Held
55.1MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$373 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$128 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$127 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$110 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$84.4 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.5B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...